Hemopexin therapy reverts heme-induced proinflammatory phenotypic switching of macrophages in a mouse model of sickle cell disease

Blood

Volumn 127, Issue 4, 2016, Pages 473-486

  Vinchi, Francesca ^a,b   Da Silva, Milene Costa ^a,c,d   Ingoglia, Giada ^b   Petrillo, Sara ^b   Brinkman, Nathan ^e   Zuercher, Adrian ^f   Cerwenka, Adelheid ^d   Tolosano, Emanuela ^b   Muckenthaler, Martina U ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF PORTO   (Portugal)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e Research and Development   (United States)

^f CSL Behring   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CD14 ANTIGEN; COLLAGENASE 3; GELATINASE B; HEME; HEMOGLOBIN; HEMOPEXIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE ELASTASE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR; REACTIVE OXYGEN METABOLITE; SMOOTH MUSCLE ACTIN; SYNAPTOPHYSIN; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; CYTOKINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL TRANSDIFFERENTIATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ERYTHROCYTE; ERYTHROPHAGOCYTOSIS; LEUKOCYTE; MACROPHAGE FUNCTION; MOUSE; NONHUMAN; PHENOTYPE; PHENOTYPIC PLASTICITY; POLARIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENESCENCE; SICKLE CELL ANEMIA; SPLEEN; UPREGULATION; VASCULAR ENDOTHELIUM; ANEMIA, SICKLE CELL; ANIMAL; CELL CULTURE; CELL LINE; DISEASE MODEL; DRUG EFFECTS; GENE DELETION; GENETICS; HUMAN; IMMUNOLOGY; KNOCKOUT MOUSE; MACROPHAGE; PATHOLOGY;

ANEMIA, SICKLE CELL; ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL LINE; CELLS, CULTURED; CYTOKINES; DISEASE MODELS, ANIMAL; GENE DELETION; HEME; HEMOPEXIN; HUMANS; MACROPHAGES; MICE; MICE, KNOCKOUT; REACTIVE OXYGEN SPECIES; TOLL-LIKE RECEPTOR 4;

EID: 84958078769     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-08-663245     Document Type: Article

References (71)

1. Tolosano E, Fagoonee S, Morello N, Vinchi F, Fiorito V. Heme scavenging and the other facets of hemopexin. Antioxid Redox Signal. 2010;12(2):305-320.
2. Vinchi F, Ingoglia G, Chiabrando D, et al. Heme exporter FLVCR1a regulates heme synthesis and degradation and controls activity of cytochromes P450. Gastroenterology. 2014;146(5):1325-1338.
3. Schaer DJ, Buehler PW, Alayash AI, Belcher JD, Vercellotti GM. Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins. Blood. 2013;121(8):1276-1284.
4. Schaer DJ, Vinchi F, Ingoglia G, Tolosano E, Buehler PW. Haptoglobin, hemopexin, and related defense pathways-basic science, clinical perspectives, and drug development. Front Physiol. 2014;5:415.
5. Vinchi F, De Franceschi L, Ghigo A, et al. Hemopexin therapy improves cardiovascular function by preventing heme-induced endothelial toxicity in mouse models of hemolytic diseases. Circulation. 2013;127(12):1317-1329.
6. Vinchi F, Gastaldi S, Silengo L, Altruda F, Tolosano E. Hemopexin prevents endothelial damage and liver congestion in a mouse model of heme overload. Am J Pathol. 2008;173(1):289-299.
7. Vinchi F, Tolosano E. Therapeutic approaches to limit hemolysis-driven endothelial dysfunction: scavenging free heme to preserve vasculature homeostasis. Oxid Med Cell Longev. 2013;2013:396527.
8. Chiabrando D, Vinchi F, Fiorito V, Mercurio S, Tolosano E. Heme in pathophysiology: a matter of scavenging, metabolism and trafficking across cell membranes. Front Pharmacol. 2014;5:61.
9. Schaer DJ, Buehler PW. Cell-free hemoglobin and its scavenger proteins: new disease models leading the way to targeted therapies. Cold Spring Harb Perspect Med. 2013;3(6):a013433.
10. Gozzelino R, Jeney V, Soares MP. Mechanisms of cell protection by heme oxygenase-1. Annu Rev Pharmacol Toxicol. 2010;50:323-354.
11. Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two to tango: regulation of Mammalian iron metabolism. Cell. 2010;142(1):24-38.
12. Marro S, Chiabrando D, Messana E, et al. Heme controls ferroportin1 (FPN1) transcription involving Bach1, Nrf2 and a MARE/ARE sequence motif at position-7007 of the FPN1 promoter. Haematologica. 2010;95(8):1261-1268.
13. De Franceschi L. Pathophisiology of sickle cell disease and new drugs for the treatment. Mediterr J Hematol Infect Dis. 2009;1(1):e2009024.
14. Walter PB, Harmatz P, Vichinsky E. Iron metabolism and iron chelation in sickle cell disease. Acta Haematol. 2009;122(2-3):174-183.
15. Muller-Eberhard U, Javid J, Liem HH, Hanstein A, Hanna M. Plasma concentrations of hemopexin, haptoglobin and heme in patients with various hemolytic diseases. Blood. 1968;32(5):811-815.
16. Boretti FS, Buehler PW, D'Agnillo F, et al. Sequestration of extracellular hemoglobin within a haptoglobin complex decreases its hypertensive and oxidative effects in dogs and guinea pigs. J Clin Invest. 2009;119(8):2271-2280.
17. Belcher JD, Chen C, Nguyen J, et al. Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease. Blood. 2014;123(3):377-390.
18. Dutra FF, Alves LS, Rodrigues D, et al. Hemolysis-induced lethality involves inflammasome activation by heme. Proc Natl Acad Sci USA. 2014;111(39):E4110-E4118.
19. Fortes GB, Alves LS, de Oliveira R, et al. Heme induces programmed necrosis on macrophages through autocrine TNF and ROS production. Blood. 2012;119(10):2368-2375.
20. Figueiredo RT, Fernandez PL, Mourao-Sa DS, et al. Characterization of heme as activator of Toll-like receptor 4. J Biol Chem. 2007;282(28):20221-20229.
21. Fernandez PL, Dutra FF, Alves L, et al. Heme amplifies the innate immune response to microbial molecules through spleen tyrosine kinase (Syk) - dependent reactive oxygen species generation. J Biol Chem. 2010;285(43):32844-32851.
22. Porto BN, Alves LS, Fernández PL, et al. Heme induces neutrophil migration and reactive oxygen species generation through signaling pathways characteristic of chemotactic receptors. J Biol Chem. 2007;282(33):24430-24436.
23. Sakamoto TM, Canalli AA, Traina F, et al. Altered red cell and platelet adhesion in hemolytic diseases: Hereditary spherocytosis, paroxysmal nocturnal hemoglobinuria and sickle cell disease. Clin Biochem. 2013;46(18):1798-1803.
24. Jison ML, Munson PJ, Barb JJ, et al. Blood mononuclear cell gene expression profiles characterize the oxidant, hemolytic, and inflammatory stress of sickle cell disease. Blood. 2004;104(1):270-280.
25. Francis RB Jr, Haywood LJ. Elevated immunoreactive tumor necrosis factor and interleukin-1 in sickle cell disease. J Natl Med Assoc. 1992;84(7):611-615.
26. Malavé I, Perdomo Y, Escalona E, et al. Levels of tumor necrosis factor alpha/cachectin (TNF alpha) in sera from patients with sickle cell disease. Acta Haematol. 1993;90(4):172-176.
27. Croizat H. Circulating cytokines in sickle cell patients during steady state. Br J Haematol. 1994;87(3):592-597.
28. Kuvibidila S, Gardner R, Ode D, Yu L, Lane G, Warrier RP. Tumor necrosis factor alpha in children with sickle cell disease in stable condition. J Natl Med Assoc. 1997;89(9):609-615.
29. Mohapatra PC, Sarangi A, Sarangi AK, Dalai RK, Sahoo D. Sequential serum cytokine levels of TNF-alpha, IL-4 and IL-12 are associated with prognosis in Plasmodium falciparum malaria. Indian J Clin Biochem. 2014;29(3):321-326.
30. Ferreira A, Balla J, Jeney V, Balla G, Soares MP. A central role for free heme in the pathogenesis of severe malaria: the missing link? J Mol Med (Berl). 2008;86(10):1097-1111.
31. Netea MG, van der Meer JW, van Deuren M, Kullberg BJ. Proinflammatory cytokines and sepsis syndrome: not enough, or too much of a good thing? Trends Immunol. 2003;24(5):254-258.
32. Larsen R, Gozzelino R, Jeney V, et al. A central role for free heme in the pathogenesis of severe sepsis. Sci Transl Med. 2010;2(51):51ra71.
33. de Jong HK, van der Poll T, Wiersinga WJ. The systemic pro-inflammatory response in sepsis. J Innate Immun. 2010;2(5):422-430.
34. Adamzik M, Hamburger T, Petrat F, Peters J, de Groot H, Hartmann M. Free hemoglobin concentration in severe sepsis: methods of measurement and prediction of outcome. Crit Care. 2012;16(4):R125.
35. Madrid-Miller A, Chávez-Sánchez L, Careaga-Reyna G, et al. Clinical outcome in patients with acute coronary syndrome and outward remodeling is associated with a predominant inflammatory response. BMC Res Notes. 2014;7:669.
36. Battes LC, Cheng JM, Oemrawsingh RM, et al. Circulating cytokines in relation to the extent and composition of coronary atherosclerosis: results from the ATHEROREMO-IVUS study. Atherosclerosis. 2014;236(1):18-24.
37. Zhou Y, Wang Y, Wang J, Anne Stetler R, Yang QW. Inflammation in intracerebral hemorrhage: from mechanisms to clinical translation. Prog Neurobiol. 2014;115:25-44.
38. Lin S, Yin Q, Zhong Q, et al. Heme activates TLR4-mediated inflammatory injury via MyD88/TRIF signaling pathway in intracerebral hemorrhage. J Neuroinflammation. 2012;9:46.
39. Larsen R, Gouveia Z, Soares MP, Gozzelino R. Heme cytotoxicity and the pathogenesis of immune-mediated inflammatory diseases. Front Pharmacol. 2012;3:77.
40. Belcher JD, Marker PH, Weber JP, Hebbel RP, Vercellotti GM. Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion. Blood. 2000;96(7):2451-2459.
41. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012;122(3):787-795.
42. Mantovani A, Biswas SK, Galdiero MR, Sica A, Locati M. Macrophage plasticity and polarization in tissue repair and remodelling. J Pathol. 2013;229(2):176-185.
43. Chinetti-Gbaguidi G, Staels B. Macrophage polarization in metabolic disorders: functions and regulation. Curr Opin Lipidol. 2011;22(5):365-372.
44. Butcher MJ, Galkina EV. Phenotypic and functional heterogeneity of macrophages and dendritic cell subsets in the healthy and atherosclerosis-prone aorta. Front Physiol. 2012;3:44.
45. Leitinger N, Schulman IG. Phenotypic polarization of macrophages in atherosclerosis. Arterioscler Thromb Vasc Biol. 2013;33(6):1120-1126.
46. Recalcati S, Locati M, Marini A, et al. Differential regulation of iron homeostasis during human macrophage polarized activation. Eur J Immunol. 2010;40(3):824-835.
47. Corna G, Campana L, Pignatti E, et al. Polarization dictates iron handling by inflammatory and alternatively activated macrophages. Haematologica. 2010;95(11):1814-1822.
48. Cairo G, Recalcati S, Mantovani A, Locati M. Iron trafficking and metabolism in macrophages: contribution to the polarized phenotype. Trends Immunol. 2011;32(6):241-247.
49. Nairz M, Schroll A, Demetz E, Tancevski I, Theurl I, Weiss G. 'Ride on the ferrous wheel' - The cycle of iron in macrophages in health and disease. Immunobiology. 2014; (Sep): 16.
50. Win N, Lee E, Needs M, Chia LW, Stasi R. Measurement of macrophage marker in hyperhaemolytic transfusion reaction: a case report. Transfus Med. 2012;22(2):137-141.
51. Tolosano E, Cutufia MA, Hirsch E, Silengo L, Altruda F. Specific expression in brain and liver driven by the hemopexin promoter in transgenic mice. Biochem Biophys Res Commun. 1996;218(3):694-703.
52. Hoshino K, Takeuchi O, Kawai T, et al. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol. 1999;162(7):3749-3752.
53. Ryan TM, Ciavatta DJ, Townes TM. Knockouttransgenic mouse model of sickle cell disease. Science. 1997;278(5339):873-876.
54. Lin T, Kwak YH, Sammy F, et al. Synergistic inflammation is induced by blood degradation products with microbial Toll-like receptor agonists and is blocked by hemopexin. J Infect Dis. 2010;202(4):624-632.
55. Tacke F, Zimmermann HW. Macrophage heterogeneity in liver injury and fibrosis. J Hepatol. 2014;60(5):1090-1096.
56. Recalcati S, Locati M, Gammella E, Invernizzi P, Cairo G. Iron levels in polarized macrophages: regulation of immunity and autoimmunity. Autoimmun Rev. 2012;11(12):883-889.
57. Haldar M, Kohyama M, So AY, et al. Hememediated SPI-C induction promotes monocyte differentiation into iron-recycling macrophages. Cell. 2014;156(6):1223-1234.
58. Sindrilaru A, Peters T, Wieschalka S, et al. An unrestrained proinflammatory M1 macrophage population induced by iron impairs wound healing in humans and mice. J Clin Invest. 2011;121(3):985-997.
59. Nieuwenhuizen L, Schutgens RE, Coeleveld K, et al. Hemarthrosis in hemophilic mice results in alterations in M1-M2 monocyte/macrophage polarization. Thromb Res. 2014;133(3):390-395.
60. Boyle JJ. Heme and haemoglobin direct macrophage Mhem phenotype and counter foam cell formation in areas of intraplaque haemorrhage. Curr Opin Lipidol. 2012;23(5):453-461.
61. Boyle JJ, Harrington HA, Piper E, et al. Coronary intraplaque hemorrhage evokes a novel atheroprotective macrophage phenotype. Am J Pathol. 2009;174(3):1097-1108.
62. Boyle JJ, Johns M, Kampfer T, et al. Activating transcription factor 1 directs Mhem atheroprotective macrophages through coordinated iron handling and foam cell protection. Circ Res. 2012;110(1):20-33.
63. Yuan XM, Anders WL, Olsson AG, Brunk UT. Iron in human atheroma and LDL oxidation by macrophages following erythrophagocytosis. Atherosclerosis. 1996;124(1):61-73.
64. Finn AV, Nakano M, Polavarapu R, et al. Hemoglobin directs macrophage differentiation and prevents foam cell formation in human atherosclerotic plaques. J Am Coll Cardiol. 2012;59(2):166-177.
65. Hvidberg V, Maniecki MB, Jacobsen C, Højrup P, Møller HJ, Moestrup SK. Identification of the receptor scavenging hemopexin-heme complexes. Blood. 2005;106(7):2572-2579.
66. Rolla S, Ingoglia G, Bardina V, et al. Acute-phase protein hemopexin is a negative regulator of Th17 response and experimental autoimmune encephalomyelitis development. J Immunol. 2013;191(11):5451-5459.
67. Lin T, Sammy F, Yang H, et al. Identification of hemopexin as an anti-inflammatory factor that inhibits synergy of hemoglobin with HMGB1 in sterile and infectious inflammation. J Immunol. 2012;189(4):2017-2022.
68. Liang X, Lin T, Sun G, Beasley-Topliffe L, Cavaillon JM, Warren HS. Hemopexin down-regulates LPSinduced proinflammatory cytokines from macrophages. J Leukoc Biol. 2009;86(2):229-235.
69. Ghosh S, Adisa OA, Chappa P, et al. Extracellular hemin crisis triggers acute chest syndrome in sickle mice. J Clin Invest. 2013;123(11):4809-4820.
70. Chies JA, Nardi NB. Sickle cell disease: a chronic inflammatory condition. Med Hypotheses. 2001;57(1):46-50.
71. Platt OS. Sickle cell anemia as an inflammatory disease. J Clin Invest. 2000;106(3):337-338.